


SCHEME 5




105750" 30720000

## SCHEME 5

- Compounds of FORMULA I, wherein  $X_1$  is  $CH_2$  are prepared starting with commercially accessible intermediate  $A_{11}$ . Reduction of the carboxylic acid functionality in  $A_{11}$  with e g; diborane or lithium aluminum hydride gives the hydroxymethyl derivative which may be elaborated to  $CH_2CO_2R$  functionality using the methodology elaborated in EXAMPLE 1.
- Demethylation of the intermediate with a boron trihalide such as boron tribromide, boron trichloride gives the demethylated intermediates  $A_{13}$  which is processed to the compounds of Formula I by synthetic transformations as outlined in SCHEME 1

09582186 061501

# **SCHEME 6**




## SCHEME 6

The compounds of FORMULA I, wherein A<sup>1</sup> is substituted pyridyl may be prepared by adopting the general synthetic SCHEME 6. For  
5 example, reaction of substituted 2-halopyridine N-oxide (such as A<sub>19a</sub>-A<sub>19d</sub>) with e. g. 3-aminopropanol gives the intermediates A<sub>20a</sub>-A<sub>20d</sub>. This reaction may preferentially be carried out by refluxing the intermediate 2-halopyridine N-oxide (such as 2-chloropyridine N-oxide) in solvents such as tert-butyl alcohol, tert-amyl alcohol in the presence of base (such as sodium  
10 bicarbonate, sodium carbonate, potassium carbonate, potassium bicarbonate). The preparative conditions described in WO 99/15508 (PCT US 98/19466) may be used for this transformation.



Coupling of the intermediates A<sub>20a</sub>-A<sub>20d</sub> with A<sub>16</sub> using Mitsunobu  
15 reaction gives the compounds containing the ether link. This reaction may preferentially be carried out using triarylphosphine (such as triphenylphosphine) and dialkylazodicarboxylate (such as diethyl azodicarboxylate, di-tert-butyl azodicarboxylate, di-iso-propyl azodicarboxylate) in solvents such as DMF, methylene chloride, or THF. N-Deoxygenation of resulting  
intermediates followed by hydrolysis of the ester gives the compounds  
20 (A<sub>21a</sub>-A<sub>21d</sub>).

Reduction of the N-oxide bond may be accomplished using e. g., transfer hydrogenation (cyclohexene/Pd on carbon) or ammonium formate and Pd on carbon. The nitro group in A<sub>21d</sub> may be hydrogenated using Pd on carbon or Pt on carbon as catalysts. This transformation may be carried  
25 out using solvents such as methanol, ethanol or THF. The hydrolysis of the ester group may be carried using aqueous base (such as sodium hydroxide, lithium hydroxide or potassium hydroxide) in solvents such as methanol, ethanol and THF.

Compounds of Formula I containing a heterocycle other than pyridyl  
30 can also be prepared using the methodology of SCHEME 6. For example reaction of 2-bromopyrimidine or 1-chloroisoquinoline N-oxide with 3-aminopropanol gives the analogous intermediates as obtained in STEP 1 of SCHEME 6. The resulting intermediates could be elaborated as in SCHEME



1. Mitsunobu
2. Deprotection
3. Hydrolysis




10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 8

## SCHEME 7

- Compounds of FORMULA I containing 6-amino substituents may be prepared as shown in SCHEME 7. The intermediate A<sub>22b</sub> can be prepared as described in J. Med. Chem 43, 22, 2000. Boc-protected 2-amino-6-picoline (A<sub>22a1</sub>) or its ethylated derivative (A<sub>22c1</sub>) are elaborated to A<sub>22a</sub> and A<sub>22c</sub> as shown for case A<sub>22b</sub> in the above publication. The ethylated intermediate A<sub>22c1</sub> may be prepared from A<sub>22a1</sub> by alkylation using e. g.; EtI and a base such as potassium carbonate, cesium carbonate. This reaction may preferentially be carried out in polar solvents such as dimethylformamide, or dimethylacetamide. Mitsunobu reaction of A<sub>16</sub>, gives the compounds containing the phenol ether. Removal of Boc group using e. g., trifluoroacetic acid, in solvents such as dichloromethane, followed by hydrolysis of the ester group as discussed in SCHEME 6 above gives the compounds (A<sub>23a</sub>-A<sub>23c</sub>).

### EXAMPLE A

2-[3-hydroxy-1-propylamino]pyridine-*N*-oxide:




5

- A mixture of 2-chloropyridine-*N*-oxide ( 16.6 g, 100 mmoles), 3-amino-1-propanol ( 15.3 ml, 200 mmoles ),  $\text{NaHCO}_3$  ( 42 g, 0.5 mole ), and tert-amyl alcohol ( 100 ml ) was heated to reflux. After 23 hours, the reaction was
- 10 cooled, diluted with  $\text{CH}_2\text{Cl}_2$  ( 300 ml ), and filtered to remove insoluble materials. The filtrate was concentrated to afford a brown oil. The oil was dried under vacuum overnight. Ether (100 ml) was added to give a brown solid. The ether was decanted and the solid was washed further with ether/acetonitrile (3/1). The resulting solid was heated at  $67^\circ\text{C}$  under
- 15 vacuum to give the desired product (13.5 g).  $^1\text{H}$  NMR was consistent with the proposed structure.

### EXAMPLE 33

(1-Methoxymethyl-2-[4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl]-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 8.

10


SECRET



EXAMPLE 34

(1-Methanesulfonylmethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 8.


10

0000105-051501

EXAMPLE 35

(1-Pyridin-3-yl-2-(4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl)-cyclopropyl)-acetic acid

5




The title compound is prepared according to the general procedures described in SCHEME 8.

10

0000105-051501  
F051501-0012000

5




10

[illegible]

-130-

5




10

*[The following text is extremely faint and appears to be bleed-through from the reverse side of the page. It contains several lines of illegible handwriting.]*

-131-

5




10

THE NEW YORK PUBLIC LIBRARY  
ASTOR LENOX TILDEN FOUNDATIONS  
155 E. 42ND STREET  
NEW YORK 17, N. Y.

-132-


5



**10.**

1. The first part of the report is a general statement of the purpose of the study.

5




10

[illegible]

1. The first part of the document is a list of names and addresses, which appears to be a directory or a list of contacts. The names are listed in a column, and the addresses are listed in a column next to them.

5




10



EXAMPLE 42

(2-[4-[3-(1-*H*-Imidazol-2-ylamino)-propoxy]-phenyl]-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures described in SCHEME 9.

10


05052136 10:15:04

-136-

### EXAMPLE 43

(2-{3-Fluoro-4-[3-(1-*H*-imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-  
acetic acid

5




The title compound is prepared according to the general procedures described in SCHEME 9.

10

FOI 302 30120060

-137

5




10

1. The first part of the report, which is the most important, is the introduction. This part should be written in a clear and concise manner, and should provide a brief overview of the project and its objectives. It should also include a statement of the problem being addressed, and a description of the methods used to collect and analyze the data.

EXAMPLE 45

(2-{4-[3-(3-*H*-Imidazol-4-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures  
described in SCHEME 9.


10

05002100 00120000

-139-

EXAMPLE 46

(2-{4-[3-(1-*H*-Pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid



5

The title compound is prepared according to the general procedures described in SCHEME 9.


10

090816 061401  
T05F90 98F28860

### EXAMPLE 47

(2-{3-Fluoro-4-[3-(1-*H*-pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 9.

10


*[Faint, illegible handwritten notes]*

-141-

EXAMPLE 48

(1-Methyl-2-{4-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-phenyl}-  
cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures  
described in SCHEME 10.

10


09062106 "061501  
101001

-142-

### EXAMPLE 49

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described, in SCHEME 10.

10

[illegible]


-143-



EXAMPLE 50

[2-(4-[2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy]-phenyl)-1-methyl-cyclopropyl]-acetic acid

5



The title compound is prepared according to the general procedures  
10 described in SCHEME 10.


1000130 061504  
F05790 3072060

-144-

EXAMPLE 51

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.

10


09602106 001501

-145-

### EXAMPLE 52

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.


10

**THE** **NEW** **YORK** **PUBLIC** **LIBRARY**

EXAMPLE 53

(2-{4-[2-(6-Acetyl-amino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.

10

05062435 "06:45:01"

-147-

The activity of the compounds of the present invention was tested in the following assays.

### VITRONECTIN ADHESION ASSAY

#### MATERIALS

Human vitronectin receptors  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were purified from human placenta as previously described [Pytela et al., Methods in Enzymology, 144:475-489 (1987)]. Human vitronectin was purified from fresh frozen plasma as previously described [Yatohgo et al., Cell Structure and Function, 13:281-292 (1988)]. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described [Charo et al., J. Biol. Chem., 266(3):1415-1421 (1991)]. Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained from Sigma (St. Louis, MO). Nalge Nunc-Immuno microtiter plates were obtained from Nalge Company (Rochester, NY).

#### METHODS

##### Solid Phase Receptor Assays

This assay was essentially the same as previously reported [Niiya et al., Blood, 70:475-483 (1987)]. The purified human vitronectin receptors  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were diluted from stock solutions to 1.0  $\mu\text{g/mL}$  in Tris-buffered saline containing 1.0 mM  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ , and  $\text{Mn}^{++}$ , pH 7.4 ( $\text{TBS}^{+++}$ ). The diluted receptors were immediately transferred to Nalge Nunc-Immuno microtiter plates at 100  $\mu\text{L/well}$  (100 ng receptor/well). The plates were sealed and incubated overnight at 4°C to allow the receptors to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200  $\mu\text{L}$  of 1% RIA grade BSA in  $\text{TBS}^{+++}$  ( $\text{TBS}^{+++}/\text{BSA}$ ) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with  $\text{TBS}^{+++}$  using a 96 well plate

-148-

03062106.061501  
T05T90.98F2850

washer. Logarithmic serial dilution of the test compound and controls were made starting at a stock concentration of 2 mM and using 2 nM biotinylated vitronectin in TBS<sup>++</sup>/BSA as the diluent. This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50  $\mu$ L aliquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was  $1.0 \times 10^{-4}$  M. The competition occurred for two hours after which all wells were washed with a plate washer as before. Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1:2000 in TBS<sup>++</sup>/BSA and 125  $\mu$ L was added to each well. After 45 minutes, the plates were washed and incubated with OPD/H<sub>2</sub>O<sub>2</sub> substrate in 100 mM/L Citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absorbance of about 1.0, the final A<sub>450</sub> were recorded for analysis. The data were analyzed using a macro written for use with the EXCEL spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations. The mean A<sub>450</sub> values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX). The normalized values were subjected to a four parameter curve fit algorithm [Rodbard et al., Int. Atomic Energy Agency, Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC<sub>50</sub>) and corresponding R<sup>2</sup> was reported for those compounds exhibiting greater than 50% inhibition at the highest concentration tested; otherwise the IC<sub>50</sub> is reported as being greater than the highest concentration tested.  $\beta$ -[[2-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-1-oxoethyl]amino]-3-pyridinepropanoic acid [US 5,602,155 Example 1] which is a potent  $\alpha_w\beta_3$  antagonist (IC<sub>50</sub> in the range 3-10 nM) was included on each plate as a positive control.

#### PURIFIED IIb/IIIa RECEPTOR ASSAY

#### MATERIALS

-149-

Human fibrinogen receptor (IIb/IIIa) was purified from outdated platelets. (Pytela, R., Pierschbacher, M.D., Argaves, S., Suzuki, S., and Rouslahti, E. "Arginine-Glycine-Aspartic acid adhesion receptors", Methods in Enzymology 144(1987):475-489.) Human vitronectin was purified from  
5 fresh frozen plasma as described in Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M., "Novel purification of vitronectin from human plasma by heparin affinity chromatography," Cell Structure and Function 13(1988):281-292. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to  
10 purified vitronectin as previously described. (Charo, I.F., Nannizzi, L., Phillips, D.R., Hsu, M.A., Scarborough, R.M., "Inhibition of fibrinogen binding to GP IIb/IIIa by a GP IIIa peptide", J. Biol. Chem. 266(3)(1991): 1415-1421.) Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained  
15 from Sigma (St. Louis, MO). Nalge Nunc-Immuno microtiter plates were obtained from (Rochester, NY). ADP reagent was obtained from Sigma (St. Louis, MO).

## METHODS

20

### Solid Phase Receptor Assays

This assay is essentially the same reported in Niiya, K., Hodson, E., Bader, R., Byers-Ward, V. Koziol, J.A., Plow, E.F. and Ruggeri, Z.M.,  
25 "Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation: Relationships to the binding of fibrinogen and platelet aggregation", Blood 70(1987):475-483. The purified human fibrinogen receptor (IIb/IIIa) was diluted from stock solutions to 1.0  $\mu\text{g/mL}$  in Tris-buffered saline containing 1.0 mM  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ , and  $\text{Mn}^{++}$ , pH  
30 7.4 ( $\text{TBS}^{+++}$ ). The diluted receptor was immediately transferred to Nalge Nunc-Immuno microtiter plates at 100  $\mu\text{L/well}$  (100 ng receptor/well). The plates were sealed and incubated overnight at 4°C to allow the receptors to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200  $\mu\text{L}$  of 1% RIA grade BSA in  $\text{TBS}^{+++}$

-150-

(TBS<sup>+++</sup>/BSA) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with TBS<sup>+++</sup> using a 96 well plate washer. Logarithmic serial dilution of the test compound and controls were made starting at a stock concentration of 2 mM and using 2 nM biotinylated vitronectin in TBS<sup>+++</sup>/BSA as the diluent. This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50  $\mu$ L aliquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was  $1.0 \times 10^{-4}$  M. The competition occurred for two hours after which all wells were washed with a plate washer as before. Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1:2000 in TBS<sup>+++</sup>/BSA and 125  $\mu$ L were added to each well. After 45 minutes, the plates were washed and incubated with ODD/H<sub>2</sub>O<sub>2</sub> substrate in 100 mM/L citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absorbance of about 1.0, the final A<sub>450</sub> were recorded for analysis. The data were analyzed using a macro written for use with the EXCELJ spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations. The mean A<sub>450</sub> values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX). The normalized values were subjected to a four parameter curve fit algorithm, [Robard et al., Int. Atomic Energy Agency, Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC<sub>50</sub>) and corresponding R<sup>2</sup> was reported for those compounds exhibiting greater than 50% inhibition at the highest concentration tested; otherwise the IC<sub>50</sub> is reported as being greater than the highest concentration tested.  $\beta$ -[[2-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-1-oxoethyl]amino]-3-pyridinepropanoic acid [US 5,602,155 Example 1] which is a potent  $\alpha_v\beta_3$  antagonist (IC<sub>50</sub> in the range 3-10 nM) was included on each plate as a positive control.

### Human Platelet Rich Plasma Assays

-151-



FOI b7D b7C b7E

Healthy aspirin free donors were selected from a pool of volunteers. The harvesting of platelet rich plasma and subsequent ADP induced platelet aggregation assays were performed as described in Zucker, M.B.,  
5 "Platelet Aggregation Measured by the Photometric Method", Methods in Enzymology 169(1989):117-133. Standard venipuncture techniques using a butterfly allowed the withdrawal of 45 mL of whole blood into a 60 mL syringe containing 5 mL of 3.8% trisodium citrate. Following thorough mixing in the syringe, the anti-coagulated whole blood was transferred to a  
10 50 mL conical polyethylene tube. The blood was centrifuged at room temperature for 12 minutes at 200 xg to sediment non-platelet cells. Platelet rich plasma was removed to a polyethylene tube and stored at room temperature until used. Platelet poor plasma was obtained from a second centrifugation of the remaining blood at 2000 xg for 15 minutes.  
15 Platelet counts are typically 300,000 to 500,000 per microliter. Platelet rich plasma (0.45 mL) was aliquoted into siliconized cuvettes and stirred (1100 rpm) at 37°C for 1 minute prior to adding 50 uL of pre-diluted test compound. After 1 minute of mixing, aggregation was initiated by the addition of 50 uL of 200 uM ADP. Aggregation was recorded for 3 minutes  
20 in a Payton dual channel aggregometer (Payton Scientific, Buffalo, NY). The percent inhibition of maximal response (saline control) for a series of test compound dilutions was used to determine a dose response curve. All compounds were tested in duplicate and the concentration of half-maximal inhibition ( $IC_{50}$ ) was calculated graphically from the dose response curve for  
25 those compounds which exhibited 50% or greater inhibition at the highest concentration tested; otherwise, the  $IC_{50}$  is reported as being greater than the highest concentration tested.

-152-